drugset

drugset / Trial / NCT07832747

A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT

NCT07832747 ↗

Phase 2 Not yet recruiting 18 enrolled Ono Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety, and pharmacokinetics of DCC-3014 in subjects with Tenosynovial Giant Cell Tumor

Timeline

Start: 2026-10-31
Primary completion: 2028-08-31
Completion: 2030-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vimseltinib	Small molecule	30 mg	Oral

Indications